SLU-PP-332 and BAM15 are research-only metabolic compounds with striking mouse data and no human trials. Compare their mechanisms, dosing gaps, and safety.
SLU-PP-332 and BAM15 are two separate research chemicals that both produced dramatic metabolic changes in mice, and neither one is approved for human use. SLU-PP-332 activates estrogen-related receptors to mimic some effects of exercise, while BAM15 is a mitochondrial uncoupler that makes cells burn fuel as heat. The search phrase slu pp 332 bam 15 usually comes from people wondering whether the two should be stacked for fat loss — a question that no published study has ever tested.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors, known as ERR alpha, beta, and gamma. A 2023 study from Washington University described the compound as an exercise mimetic because it switched on gene programs normally activated by endurance training.
- Mice treated with SLU-PP-332 ran longer and resisted fatigue better than untreated animals.
- Obese mice lost fat mass and showed improved metabolic markers.
- The animals did not eat less or move more, according to the published rodent data.
Research into slu-pp-332 benefits is still early stage. Every notable finding comes from animal models, and no controlled human trial has been published.
What Is BAM15?
BAM15 belongs to a class called mitochondrial protonophores, or uncouplers. It lets protons leak across the inner mitochondrial membrane so that cells burn fuel without capturing all of it as ATP, releasing the difference as heat.
BAM15 stood out in mouse research because it reduced body fat without raising core temperature or suppressing appetite, and it improved insulin sensitivity. That profile distinguished it from older uncouplers such as DNP, which were abandoned in humans decades ago after causing dangerous hyperthermia.
BAM15 is not a drug. It is a laboratory tool, and its human safety profile is completely unknown.
SLU-PP-332 vs BAM15 at a Glance
| Feature | SLU-PP-332 | BAM15 |
|---|---|---|
| Primary mechanism | ERR receptor agonist that changes gene transcription | Mitochondrial uncoupler that creates a proton leak |
| Where it acts | Cell nucleus and receptor signaling | Inner mitochondrial membrane |
| Main rodent findings | Greater endurance, less fatigue, lower fat mass | Lower fat mass, better insulin sensitivity, no hyperthermia |
| Route used in studies | Injectable in mice | Oral gavage in mice |
| Human trials | None published | None published |
| Regulatory status | Research chemical, not FDA-approved | Research chemical, not FDA-approved |
Why People Mention Them Together
The two compounds get discussed side by side because they push body composition from opposite directions. SLU-PP-332 changes which genes are switched on, and BAM15 changes how efficiently mitochondria turn fuel into usable energy. In theory, that could hit two separate levers of energy expenditure at once.
That theory is untested. No study has combined SLU-PP-332 and BAM15 in any species, and there is no data on whether they interact, compound each other's effects, or raise risk.
Online comparisons follow the same pattern. Discussions of slu-pp-332 vs 5-amino-1mq rest on mechanism and rodent data rather than human outcomes, and the same caveat applies to slu-pp-332 vs mots-c conversations, where compounds are contrasted by target tissue instead of by controlled results.
Human Dosing Information: What Exists
Nothing reliable. Any figure you see for a slu-pp-332 oral dosage per day comes from vendor pages, forum posts, or research-chemical resellers — not from pharmacokinetic or safety studies in people. Questions about slu-pp-332 oral vs injection are equally unresolved, because no human study has compared absorption by route.
For BAM15, the situation is even thinner. The history of this drug class is a warning rather than a template: early uncouplers caused severe hyperthermia in people, and the therapeutic window for protonophores is narrow.
Before trusting a claim about either compound, ask three questions:
- Is the source a peer-reviewed human trial or a rodent study?
- Does it quote a dose, or only a mechanism?
- Does the seller also profit from the claim?
Safety, Storage, and Legal Status
SLU-PP-332 is not FDA-approved for human use in the United States, and neither is BAM15. Both are sold as research chemicals, which means they are not dietary supplements, they carry no established human dose, and selling them for human consumption is not legal.
Nobody knows the long-term risks of either compound in people. Uncouplers can interfere with temperature regulation, and receptor agonists that alter gene transcription can affect tissues far beyond fat and muscle. Anyone considering these substances should talk with a healthcare professional rather than rely on forum guidance.
Handling rules matter in a lab setting. Researchers who ask how to store bpc 157 typically receive the same general advice that applies here: keep material sealed in its original vial, protect it from light and moisture, and follow the supplier's temperature instructions.
No human trial has tested SLU-PP-332 or BAM15, alone or in combination.
The bottom line is simple. SLU-PP-332 and BAM15 are interesting preclinical compounds with genuinely surprising rodent data, and they are also unproven, unapproved, and untested in people. Curiosity about the mechanism is reasonable; treating either one as a proven fat-loss tool is not.
Frequently Asked Questions
Is SLU-PP-332 or BAM15 approved for human use?
No. Neither SLU-PP-332 nor BAM15 is FDA-approved for human use, and neither has completed a human clinical trial. Both are sold as research chemicals intended for laboratory study only, which means they have no established human dose and no verified safety profile.
Can you stack SLU-PP-332 with BAM15?
No published study has combined SLU-PP-332 and BAM15 in any species, including mice. Because the compounds work through different pathways, researchers cannot predict how they would interact in a living body, and stacking untested substances increases the chance of unknown side effects.
What is the main difference between SLU-PP-332 and BAM15?
SLU-PP-332 is an ERR receptor agonist that alters gene transcription and behaves like an exercise mimetic in mice. BAM15 is a mitochondrial uncoupler that makes cells release energy as heat instead of storing it as ATP. One acts on gene signaling, and the other acts directly on mitochondrial efficiency.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.